Literature DB >> 11439335

The monoclonal antibody 225 activates caspase-8 and induces apoptosis through a tumor necrosis factor receptor family-independent pathway.

B Liu1, Z Fan.   

Abstract

We previously reported that the anti-epidermal growth factor (EGF) receptor monoclonal antibody (mAb) 225 induces DiFi colon cancer cells to undergo apoptosis, and this apoptosis was accompanied by activation of the two apoptosis initiation caspases, caspase-8 and caspase-9. In the current study, we found that pretreatment of DiFi cells with the caspase-8-specific inhibitor z-IETD-fmk but not pretreatment with the caspase-9-specific inhibitor z-LEHD-fmk inhibited mAb 225-induced apoptosis, indicating that caspase-8 plays an essential role in initiating mAb 225-induced apoptosis. Because caspase-8 is activated primarily by the members of the tumor necrosis factor (TNF) receptor family, such as Fas, TNF receptor-1 (TNFR1), or receptors for TNF-related apoptosis-inducing ligand (TRAIL), we investigated whether mAb 225 activated caspase-8 by regulating one or more of these known pathways. Exposure of DiFi cells to TNFalpha or TRAIL activated caspase-8 and induced apoptosis in the cells. A TNFR1-antagonistic mAb or a TRAIL decoy receptor inhibited the activation of caspase-8 and the subsequent apoptosis induced by TNFalpha or TRAIL, respectively, in the cells. However, neither the TNFR1-antagonistic mAb nor the TRAIL decoy receptor inhibited mAb 225-induced activation of caspase-8 and apoptosis in DiFi cells. DiFi cells express detectable level of Fas but are not sensitive to the treatment by the Fas-agonistic mAb CH-11. A Fas-antagonistic mAb (ZB-4) inhibited the Fas-agonistic mAb CH-11-induced caspase-8 activation and apoptosis in Jurkat T-leukemic cells (used as positive control), but had no effect on mAb 225-induced activation of caspase-8 and apoptosis in DiFi cells. Taken together, our results suggest that mAb 225 does not interact with or regulate these known death receptor pathways. An exploration is therefore warranted for a novel mechanism by which mAb 225 activates caspase-8 and triggers apoptosis in DiFi cells.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11439335     DOI: 10.1038/sj.onc.1204490

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  9 in total

1.  Roles of autophagy in cetuximab-mediated cancer therapy against EGFR.

Authors:  Xinqun Li; Yang Lu; Tianhong Pan; Zhen Fan
Journal:  Autophagy       Date:  2010-11       Impact factor: 16.016

2.  Development of anti-EGF receptor peptidomimetics (AERP) as tumor imaging agent.

Authors:  Datta E Ponde; ZiFen Su; Alan Berezov; Hongtao Zhang; Abbas Alavi; Mark I Greene; Ramachandran Murali
Journal:  Bioorg Med Chem Lett       Date:  2011-02-15       Impact factor: 2.823

3.  Cetuximab/C225-induced intracellular trafficking of epidermal growth factor receptor.

Authors:  Hong-Jun Liao; Graham Carpenter
Journal:  Cancer Res       Date:  2009-07-14       Impact factor: 12.701

4.  Expression of growth factor receptors and targeting of EGFR in cholangiocarcinoma cell lines.

Authors:  Ling Xu; Martin Hausmann; Wolfgang Dietmaier; Silvia Kellermeier; Theresa Pesch; Manuela Stieber-Gunckel; Elisabeth Lippert; Frank Klebl; Gerhard Rogler
Journal:  BMC Cancer       Date:  2010-06-18       Impact factor: 4.430

5.  17Alpha-estradiol arrests cell cycle progression at G2/M and induces apoptotic cell death in human acute leukemia Jurkat T cells.

Authors:  Do Youn Jun; Hae Sun Park; Jun Seok Kim; Jong Sik Kim; Wan Park; Bang Ho Song; Hee-Sook Kim; Dennis Taub; Young Ho Kim
Journal:  Toxicol Appl Pharmacol       Date:  2008-06-04       Impact factor: 4.219

6.  Cetuximab reverses the Warburg effect by inhibiting HIF-1-regulated LDH-A.

Authors:  Haiquan Lu; Xinqun Li; Zhongguang Luo; Jie Liu; Zhen Fan
Journal:  Mol Cancer Ther       Date:  2013-08-06       Impact factor: 6.261

7.  Acquired resistance to anti-EGFR mAb ICR62 in cancer cells is accompanied by an increased EGFR expression, HER-2/HER-3 signalling and sensitivity to pan HER blockers.

Authors:  Said A Khelwatty; Sharadah Essapen; Alan M Seddon; Zhen Fan; Helmout Modjtahedi
Journal:  Br J Cancer       Date:  2015-09-15       Impact factor: 7.640

8.  MicroRNA-579-3p Exerts Neuroprotective Effects Against Ischemic Stroke via Anti-Inflammation and Anti-Apoptosis.

Authors:  Jiaoying Jia; Yan Cui; Zhigang Tan; Wenjia Ma; Yugang Jiang
Journal:  Neuropsychiatr Dis Treat       Date:  2020-05-12       Impact factor: 2.570

9.  Identification and validation of COX-2 as a co-target for overcoming cetuximab resistance in colorectal cancer cells.

Authors:  Yang Lu; Chunmei Shi; Songbo Qiu; Zhen Fan
Journal:  Oncotarget       Date:  2016-10-04
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.